C WorldWide Group Holding A S raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 46.9% during the second quarter, Holdings Channel reports. The fund owned 121,528 shares of the biotechnology company’s stock after buying an additional 38,793 shares during the period. C WorldWide Group Holding A S’s holdings in Sarepta Therapeutics were worth $4,097,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of SRPT. BlackRock Inc. boosted its stake in shares of Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after buying an additional 5,175,193 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 4.5% in the first quarter. Vanguard Group Inc. now owns 4,096,486 shares of the biotechnology company’s stock worth $121,256,000 after buying an additional 176,966 shares during the last quarter. State Street Corp boosted its stake in shares of Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after buying an additional 559,342 shares during the last quarter. Camber Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth about $39,960,000. Finally, Emerald Advisers Inc. PA boosted its stake in shares of Sarepta Therapeutics by 6.9% in the second quarter. Emerald Advisers Inc. PA now owns 875,407 shares of the biotechnology company’s stock worth $29,510,000 after buying an additional 56,702 shares during the last quarter. 64.58% of the stock is currently owned by institutional investors and hedge funds.

Shares of Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 37.02 on Friday. The firm’s 50-day moving average is $36.95 and its 200 day moving average is $32.78. Sarepta Therapeutics, Inc. has a 52-week low of $24.31 and a 52-week high of $63.73. The stock’s market capitalization is $2.38 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue was up 350000.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.19) earnings per share. Equities analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Has $4.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-4-10-million-position-in-sarepta-therapeutics-inc-nasdaqsrpt/1474466.html.

A number of equities research analysts have issued reports on SRPT shares. Cowen and Company reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a report on Thursday, July 27th. BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Robert W. Baird reissued an “outperform” rating and set a $102.00 target price on shares of Sarepta Therapeutics in a report on Sunday, April 23rd. Finally, Leerink Swann reissued an “outperform” rating and set a $52.00 target price (up previously from $47.00) on shares of Sarepta Therapeutics in a report on Saturday, April 29th. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $61.28.

In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares in the company, valued at approximately $934,513. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Douglas S. Ingram purchased 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The stock was bought at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now owns 382,058 shares in the company, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.